EUCTR2016-003686-26-DE进行中（未招募）1 期
A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Minimum of 18 years old
- •- Participants with histologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
- •- Eastern Cooperative Oncology Group (ECOG) 0-1
- •- Adequate hematologic, hepatic, and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 54
排除标准
- •- Has active, known, or suspected autoimmune disease
- •- Had prior exposure to an immuno-oncology or pyrrolobenzodiazapine (PBD)-based drug
研究者
相似试验
进行中（未招募）
1 期
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerExtensive-Stage Small Cell Lung CancerEUCTR2016-003686-26-ESAbbVie Stemcentrx LLC90
进行中（未招募）
1 期
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Extensive-Stage Small Cell Lung CancerEUCTR2016-003686-26-ITABBVIE STEMCENTRX LLC42
已完成
不适用
Rituximab therapy for refractory pemphigusJPRN-jRCTs031180405Funakoshi Takeru20
招募中
不适用
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigusJPRN-UMIN000026004Keio University, School of Medicine20
终止
1 期
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerSmall Cell Lung CancerNCT03026166AbbVie42